VISION: 177Lu-PSMA-617 in Previously Treated Metastatic Castration-Resistant Prostate Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
In this phase III trial, addition of 177Lu-PSMA-617 to standard of care in men with previously treated PSMA-positive mCRPC prolonged OS and radiographic PFS vs standard of care alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 459 KB
Released: June 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Short slideset with the latest on next-generation AR inhibitors for nonmetastatic castration-resistant prostate cancer, from Clinical Care Options (CCO)

Karim Fizazi, MD, PhD Alicia K. Morgans, MD, MPH Released: July 30, 2021

Focused slideset from experts on the use of radium-223 and PSMA lutetium in the treatment of metastatic castration-resistant prostate cancer, from Clinical Care Options (CCO)

Chris Parker, MD Bertrand Tombal, MD, PhD Released: July 20, 2021

Use this web-based tool to see recommendations from 5 experts on treating patients with bladder cancer.

Matthew Galsky, MD person default Shilpa Gupta, MD Matthew I. Milowsky, MD Elizabeth R. Plimack, MD, MS person default Arlene O. Siefker-Radtke, MD Released: July 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue